Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 285

1.

The current state of immunotherapy for gliomas: an eye toward the future.

Fecci PE, Sampson JH.

J Neurosurg. 2019 Sep 1;131(3):657-666. doi: 10.3171/2019.5.JNS181762. Review.

PMID:
31473668
2.

Pharmacokinetic Analysis of a Novel Human EGFRvIII:CD3 Bispecific Antibody in Plasma and Whole Blood Using a High-Resolution Targeted Mass Spectrometry Approach.

Schaller TH, Foster MW, Thompson JW, Spasojevic I, Normantaite D, Moseley MA, Sanchez-Perez L, Sampson JH.

J Proteome Res. 2019 Aug 2;18(8):3032-3041. doi: 10.1021/acs.jproteome.9b00145. Epub 2019 Jul 19.

PMID:
31267741
3.

The Evolving Modern Management of Brain Metastasis.

Fecci PE, Champion CD, Hoj J, McKernan CM, Goodwin CR, Kirkpatrick JP, Anders CK, Pendergast AM, Sampson JH.

Clin Cancer Res. 2019 Jun 18. doi: 10.1158/1078-0432.CCR-18-1624. [Epub ahead of print] Review.

PMID:
31213459
4.

Reply to 'Assembling the brain trust: the multidisciplinary imperative in neuro-oncology'.

Aldape K, Brindle KM, Chesler L, Chopra R, Gajjar A, Gilbert MR, Gottardo N, Gutmann DH, Hargrave D, Holland EC, Jones DTW, Joyce JA, Kearns P, Kieran MW, Mellinghoff IK, Merchant M, Pfister SM, Pollard SM, Ramaswamy V, Rich JN, Robinson GW, Rowitch DH, Sampson JH, Taylor MD, Workman P, Gilbertson RJ.

Nat Rev Clin Oncol. 2019 Aug;16(8):522-523. doi: 10.1038/s41571-019-0236-y. No abstract available.

PMID:
31150022
5.

Single-institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice.

Desjardins A, Herndon JE 2nd, McSherry F, Ravelo A, Lipp ES, Healy P, Peters KB, Sampson JH, Randazzo D, Sommer N, Friedman AH, Friedman HS.

Health Sci Rep. 2019 Feb 13;2(4):e114. doi: 10.1002/hsr2.114. eCollection 2019 Apr.

6.

MTAP Loss Promotes Stemness in Glioblastoma and Confers Unique Susceptibility to Purine Starvation.

Hansen LJ, Sun R, Yang R, Singh SX, Chen LH, Pirozzi CJ, Moure CJ, Hemphill C, Carpenter AB, Healy P, Ruger RC, Chen CJ, Greer PK, Zhao F, Spasojevic I, Grenier C, Huang Z, Murphy SK, McLendon RE, Friedman HS, Friedman AH, Herndon JE 2nd, Sampson JH, Keir ST, Bigner DD, Yan H, He Y.

Cancer Res. 2019 Jul 1;79(13):3383-3394. doi: 10.1158/0008-5472.CAN-18-1010. Epub 2019 Apr 30.

PMID:
31040154
7.

Brain Tumor Microenvironment and Host State: Implications for Immunotherapy.

Tomaszewski W, Sanchez-Perez L, Gajewski TF, Sampson JH.

Clin Cancer Res. 2019 Jul 15;25(14):4202-4210. doi: 10.1158/1078-0432.CCR-18-1627. Epub 2019 Feb 25. Review.

PMID:
30804019
8.

Challenges to curing primary brain tumours.

Aldape K, Brindle KM, Chesler L, Chopra R, Gajjar A, Gilbert MR, Gottardo N, Gutmann DH, Hargrave D, Holland EC, Jones DTW, Joyce JA, Kearns P, Kieran MW, Mellinghoff IK, Merchant M, Pfister SM, Pollard SM, Ramaswamy V, Rich JN, Robinson GW, Rowitch DH, Sampson JH, Taylor MD, Workman P, Gilbertson RJ.

Nat Rev Clin Oncol. 2019 Aug;16(8):509-520. doi: 10.1038/s41571-019-0177-5. Review.

9.

Author Correction: Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors.

Chongsathidkiet P, Jackson C, Koyama S, Loebel F, Cui X, Farber SH, Woroniecka K, Elsamadicy AA, Dechant CA, Kemeny HR, Sanchez-Perez L, Cheema TA, Souders NC, Herndon JE, Coumans JV, Everitt JI, Nahed BV, Sampson JH, Gunn MD, Martuza RL, Dranoff G, Curry WT, Fecci PE.

Nat Med. 2019 Mar;25(3):529. doi: 10.1038/s41591-019-0355-0.

PMID:
30670876
10.

Effective effectors: How T cells access and infiltrate the central nervous system.

Congdon KL, Sanchez-Perez LA, Sampson JH.

Pharmacol Ther. 2019 May;197:52-60. doi: 10.1016/j.pharmthera.2018.12.007. Epub 2018 Dec 14. Review.

PMID:
30557632
11.

CD27 stimulation unveils the efficacy of linked class I/II peptide vaccines in poorly immunogenic tumors by orchestrating a coordinated CD4/CD8 T cell response.

Riccione KA, He LZ, Fecci PE, Norberg PK, Suryadevara CM, Swartz A, Healy P, Reap E, Keler T, Li QJ, Congdon KL, Sanchez-Perez L, Sampson JH.

Oncoimmunology. 2018 Sep 5;7(12):e1502904. doi: 10.1080/2162402X.2018.1502904. eCollection 2018.

12.

Immunotherapy for Glioblastoma: Adoptive T-cell Strategies.

Choi BD, Maus MV, June CH, Sampson JH.

Clin Cancer Res. 2019 Apr 1;25(7):2042-2048. doi: 10.1158/1078-0432.CCR-18-1625. Epub 2018 Nov 16. Review.

13.

Preventing Lck Activation in CAR T Cells Confers Treg Resistance but Requires 4-1BB Signaling for Them to Persist and Treat Solid Tumors in Nonlymphodepleted Hosts.

Suryadevara CM, Desai R, Farber SH, Choi BD, Swartz AM, Shen SH, Gedeon PC, Snyder DJ, Herndon JE 2nd, Healy P, Reap EA, Archer GE, Fecci PE, Sampson JH, Sanchez-Perez L.

Clin Cancer Res. 2019 Jan 1;25(1):358-368. doi: 10.1158/1078-0432.CCR-18-1211. Epub 2018 Nov 13.

PMID:
30425092
14.

Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors.

Chongsathidkiet P, Jackson C, Koyama S, Loebel F, Cui X, Farber SH, Woroniecka K, Elsamadicy AA, Dechant CA, Kemeny HR, Sanchez-Perez L, Cheema TA, Souders NC, Herndon JE, Coumans JV, Everitt JI, Nahed BV, Sampson JH, Gunn MD, Martuza RL, Dranoff G, Curry WT, Fecci PE.

Nat Med. 2018 Sep;24(9):1459-1468. doi: 10.1038/s41591-018-0135-2. Epub 2018 Aug 13. Erratum in: Nat Med. 2019 Mar;25(3):529.

15.

Hyaluronic acid based low viscosity hydrogel as a novel carrier for Convection Enhanced Delivery of CAR T cells.

Atik AF, Suryadevara CM, Schweller RM, West JL, Healy P, Herndon Ii JE, Congdon KL, Sanchez-Perez L, McLendon RE, Archer GE, Fecci P, Sampson JH.

J Clin Neurosci. 2018 Oct;56:163-168. doi: 10.1016/j.jocn.2018.06.005. Epub 2018 Jul 21.

16.

Recurrent Glioblastoma Treated with Recombinant Poliovirus.

Desjardins A, Gromeier M, Herndon JE 2nd, Beaubier N, Bolognesi DP, Friedman AH, Friedman HS, McSherry F, Muscat AM, Nair S, Peters KB, Randazzo D, Sampson JH, Vlahovic G, Harrison WT, McLendon RE, Ashley D, Bigner DD.

N Engl J Med. 2018 Jul 12;379(2):150-161. doi: 10.1056/NEJMoa1716435. Epub 2018 Jun 26.

17.

Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma.

Suryadevara CM, Desai R, Abel ML, Riccione KA, Batich KA, Shen SH, Chongsathidkiet P, Gedeon PC, Elsamadicy AA, Snyder DJ, Herndon JE 2nd, Healy P, Archer GE, Choi BD, Fecci PE, Sampson JH, Sanchez-Perez L.

Oncoimmunology. 2018 Feb 21;7(6):e1434464. doi: 10.1080/2162402X.2018.1434464. eCollection 2018.

18.

A simple and enzyme-free method for processing infiltrating lymphocytes from small mouse tumors for ELISpot analysis.

Swartz AM, Reap E, Norberg P, Schmittling R, Janetzki S, Sanchez-Perez L, Sampson JH.

J Immunol Methods. 2018 Aug;459:90-93. doi: 10.1016/j.jim.2018.05.015. Epub 2018 May 31.

19.

Introduction. Update on adult neuro-oncology.

Colman H, Westphal M, Sampson JH.

Neurosurg Focus. 2018 Jun;44(6):E1. doi: 10.3171/2018.3.FOCUS18149. No abstract available.

PMID:
29852765
20.

A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma.

Gedeon PC, Schaller TH, Chitneni SK, Choi BD, Kuan CT, Suryadevara CM, Snyder DJ, Schmittling RJ, Szafranski SE, Cui X, Healy PN, Herndon JE 2nd, McLendon RE, Keir ST, Archer GE, Reap EA, Sanchez-Perez L, Bigner DD, Sampson JH.

Clin Cancer Res. 2018 Aug 1;24(15):3611-3631. doi: 10.1158/1078-0432.CCR-17-0126. Epub 2018 Apr 27.

21.

Institutional Review of Mortality in 5434 Consecutive Neurosurgery Patients: Are We Improving?

Elsamadicy AA, Sergesketter A, Sampson JH, Gottfried ON.

Neurosurgery. 2018 Dec 1;83(6):1269-1276. doi: 10.1093/neuros/nyx603.

PMID:
29300938
22.

A Supramolecular Vaccine Platform Based on α-Helical Peptide Nanofibers.

Wu Y, Norberg PK, Reap EA, Congdon KL, Fries CN, Kelly SH, Sampson JH, Conticello VP, Collier JH.

ACS Biomater Sci Eng. 2017 Dec 11;3(12):3128-3132. doi: 10.1021/acsbiomaterials.7b00561. Epub 2017 Sep 11.

23.

Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - Authors' reply.

Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, Drappatz J, O'Rourke DM, Wong M, Hamilton MG, Finocchiaro G, Perry J, Wick W, Green J, He Y, Turner CD, Yellin MJ, Keler T, Davis TA, Stupp R, Sampson JH.

Lancet Oncol. 2017 Dec;18(12):e709-e710. doi: 10.1016/S1470-2045(17)30856-2. No abstract available.

PMID:
29208433
24.

Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143.

Omuro A, Vlahovic G, Lim M, Sahebjam S, Baehring J, Cloughesy T, Voloschin A, Ramkissoon SH, Ligon KL, Latek R, Zwirtes R, Strauss L, Paliwal P, Harbison CT, Reardon DA, Sampson JH.

Neuro Oncol. 2018 Apr 9;20(5):674-686. doi: 10.1093/neuonc/nox208.

25.

Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma.

Reap EA, Suryadevara CM, Batich KA, Sanchez-Perez L, Archer GE, Schmittling RJ, Norberg PK, Herndon JE 2nd, Healy P, Congdon KL, Gedeon PC, Campbell OC, Swartz AM, Riccione KA, Yi JS, Hossain-Ibrahim MK, Saraswathula A, Nair SK, Dunn-Pirio AM, Broome TM, Weinhold KJ, Desjardins A, Vlahovic G, McLendon RE, Friedman AH, Friedman HS, Bigner DD, Fecci PE, Mitchell DA, Sampson JH.

Cancer Res. 2018 Jan 1;78(1):256-264. doi: 10.1158/0008-5472.CAN-17-0469. Epub 2017 Nov 1.

26.

Obituary. Robert H. Wilkins, MD, 1934-2017.

Sampson JH, Haglund MM, Friedman AH, Ewend MG.

J Neurosurg. 2017 Dec;127(6):1457-1458. doi: 10.3171/2017.6.JNS171416. Epub 2017 Oct 13. No abstract available.

PMID:
29027856
27.

Chemokines as adjuvants for immunotherapy: implications for immune activation with CCL3.

Schaller TH, Batich KA, Suryadevara CM, Desai R, Sampson JH.

Expert Rev Clin Immunol. 2017 Nov;13(11):1049-1060. doi: 10.1080/1744666X.2017.1384313. Epub 2017 Oct 5. Review.

28.

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.

Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, Drappatz J, O'Rourke DM, Wong M, Hamilton MG, Finocchiaro G, Perry J, Wick W, Green J, He Y, Turner CD, Yellin MJ, Keler T, Davis TA, Stupp R, Sampson JH; ACT IV trial investigators.

Lancet Oncol. 2017 Oct;18(10):1373-1385. doi: 10.1016/S1470-2045(17)30517-X. Epub 2017 Aug 23.

29.

Accuracy of Novel Computed Tomography-Guided Frameless Stereotactic Drilling and Catheter System in Human Cadavers.

Sankey EW, Butler E, Sampson JH.

World Neurosurg. 2017 Oct;106:757-763. doi: 10.1016/j.wneu.2017.07.098. Epub 2017 Jul 25.

PMID:
28754645
30.

Immunotherapy for Brain Tumors.

Sampson JH, Maus MV, June CH.

J Clin Oncol. 2017 Jul 20;35(21):2450-2456. doi: 10.1200/JCO.2017.72.8089. Epub 2017 Jun 22. Review.

PMID:
28640704
31.

Vaccine-based immunotherapeutic approaches to gliomas and beyond.

Weller M, Roth P, Preusser M, Wick W, Reardon DA, Platten M, Sampson JH.

Nat Rev Neurol. 2017 Jun;13(6):363-374. doi: 10.1038/nrneurol.2017.64. Epub 2017 May 12. Review.

PMID:
28497804
32.

Biopsy of enlarging lesions after stereotactic radiosurgery for brain metastases frequently reveals radiation necrosis.

Narloch JL, Farber SH, Sammons S, McSherry F, Herndon JE, Hoang JK, Yin FF, Sampson JH, Fecci PE, Blackwell KL, Kirkpatrick JP, Kim GJ.

Neuro Oncol. 2017 Oct 1;19(10):1391-1397. doi: 10.1093/neuonc/nox090.

33.

Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination.

Batich KA, Reap EA, Archer GE, Sanchez-Perez L, Nair SK, Schmittling RJ, Norberg P, Xie W, Herndon JE 2nd, Healy P, McLendon RE, Friedman AH, Friedman HS, Bigner D, Vlahovic G, Mitchell DA, Sampson JH.

Clin Cancer Res. 2017 Apr 15;23(8):1898-1909. doi: 10.1158/1078-0432.CCR-16-2057.

34.

Immunomodulation for glioblastoma.

Reardon DA, Wen PY, Wucherpfennig KW, Sampson JH.

Curr Opin Neurol. 2017 Jun;30(3):361-369. doi: 10.1097/WCO.0000000000000451. Review.

PMID:
28368867
35.

Prospect of rindopepimut in the treatment of glioblastoma.

Elsamadicy AA, Chongsathidkiet P, Desai R, Woroniecka K, Farber SH, Fecci PE, Sampson JH.

Expert Opin Biol Ther. 2017 Apr;17(4):507-513. doi: 10.1080/14712598.2017.1299705. Epub 2017 Mar 5. Review.

36.

Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles.

Sayour EJ, De Leon G, Pham C, Grippin A, Kemeny H, Chua J, Huang J, Sampson JH, Sanchez-Perez L, Flores C, Mitchell DA.

Oncoimmunology. 2016 Nov 18;6(1):e1256527. doi: 10.1080/2162402X.2016.1256527. eCollection 2017.

37.

The Safety of available immunotherapy for the treatment of glioblastoma.

Farber SH, Elsamadicy AA, Atik AF, Suryadevara CM, Chongsathidkiet P, Fecci PE, Sampson JH.

Expert Opin Drug Saf. 2017 Mar;16(3):277-287. doi: 10.1080/14740338.2017.1273898. Epub 2017 Jan 3. Review.

38.

The clinical and financial impact of a pediatric surgical neuro-oncology clinical trial.

Thompson EM, Gururangan S, Grant G, Mitchell D, Sampson JH.

J Neurooncol. 2017 Mar;132(1):83-87. doi: 10.1007/s11060-016-2338-z. Epub 2016 Nov 18.

PMID:
27864705
39.

Immunotherapy Gone Viral: Bortezomib and oHSV Enhance Antitumor NK-Cell Activity.

Suryadevara CM, Riccione KA, Sampson JH.

Clin Cancer Res. 2016 Nov 1;22(21):5164-5166. Epub 2016 Aug 12.

40.

Advances and challenges: dendritic cell vaccination strategies for glioblastoma.

Schaller TH, Sampson JH.

Expert Rev Vaccines. 2017 Jan;16(1):27-36. Epub 2016 Aug 10. Review.

41.

Delivering therapy to target: improving the odds for successful drug development.

Raghavan R, Brady ML, Sampson JH.

Ther Deliv. 2016 Jul;7(7):457-81. doi: 10.4155/tde-2016-0016.

PMID:
27403630
42.

Advances in Immunotherapy: Abhijit Guha Award Presentation.

Sampson JH.

Neurosurgery. 2016 Aug;63 Suppl 1:85-87. doi: 10.1227/NEU.0000000000001286. No abstract available.

PMID:
27399370
43.

Rapid Reprogramming of Primary Human Astrocytes into Potent Tumor-Initiating Cells with Defined Genetic Factors.

Li F, Liu X, Sampson JH, Bigner DD, Li CY.

Cancer Res. 2016 Sep 1;76(17):5143-50. doi: 10.1158/0008-5472.CAN-16-0171. Epub 2016 Jun 30.

44.

Emerging immunotherapies for glioblastoma.

Desai R, Suryadevara CM, Batich KA, Farber SH, Sanchez-Perez L, Sampson JH.

Expert Opin Emerg Drugs. 2016 Jun;21(2):133-45. doi: 10.1080/14728214.2016.1186643. Review.

45.

Preconditioning Vaccine Sites for mRNA-Transfected Dendritic Cell Therapy and Antitumor Efficacy.

Batich KA, Swartz AM, Sampson JH.

Methods Mol Biol. 2016;1403:819-38. doi: 10.1007/978-1-4939-3387-7_47.

46.

Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy.

Saraswathula A, Reap EA, Choi BD, Schmittling RJ, Norberg PK, Sayour EJ, Herndon JE 2nd, Healy P, Congdon KL, Archer GE, Sanchez-Perez L, Sampson JH.

Cancer Immunol Immunother. 2016 Feb;65(2):205-11. doi: 10.1007/s00262-015-1784-3. Epub 2016 Jan 12.

47.

Alternating Electric Fields for the Treatment of Glioblastoma.

Sampson JH.

JAMA. 2015 Dec 15;314(23):2511-3. doi: 10.1001/jama.2015.16701. No abstract available.

PMID:
26670969
48.

Immunotherapy response assessment in neuro-oncology: a report of the RANO working group.

Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W, Ellingson BM, Hashimoto N, Pollack IF, Brandes AA, Franceschi E, Herold-Mende C, Nayak L, Panigrahy A, Pope WB, Prins R, Sampson JH, Wen PY, Reardon DA.

Lancet Oncol. 2015 Nov;16(15):e534-e542. doi: 10.1016/S1470-2045(15)00088-1. Review.

49.

Vaccination strategies for neuro-oncology.

Sampson JH, Mitchell DA.

Neuro Oncol. 2015 Nov;17 Suppl 7:vii15-vii25. doi: 10.1093/neuonc/nov159. Review.

50.

Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma.

Pham CD, Flores C, Yang C, Pinheiro EM, Yearley JH, Sayour EJ, Pei Y, Moore C, McLendon RE, Huang J, Sampson JH, Wechsler-Reya R, Mitchell DA.

Clin Cancer Res. 2016 Feb 1;22(3):582-95. doi: 10.1158/1078-0432.CCR-15-0713. Epub 2015 Sep 24.

Supplemental Content

Loading ...
Support Center